Characteristics and clinical outcomes of patients with systemic lupus erythematosus initiating anifrolumab in a real-world setting in Spain (AZAHAR study): an observational study protocol

Characteristics and clinical outcomes of patients with systemic lupus erythematosus initiating anifrolumab in a real-world setting in Spain (AZAHAR study): an observational study protocol

Introduction Anifrolumab (Saphnelo) is approved for adult patients with moderate-severe systemic lupus erythematosus (SLE). Considering its commercialisation in Spain in 2023, observational studies describing the use of anifrolumab in routine clinical practice are limited. The aim of the AZAHAR stud...

Full description

Saved in:
Bibliographic Details
Main Authors: María Galindo-Izquierdo, Josefina Cortés-Hernández, Noemí Bahamontes-Rosa, Berta Sarto-Ferres, Marta Galvez-Fernandez
Format: Article
Language:English
Published: BMJ Publishing Group 2025-02-01
Series:Lupus Science and Medicine
Online Access:https://lupus.bmj.com/content/12/1/e001486.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items